Simon Faissner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simon Faissner has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
Ralf Gold
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Gudrunstraße 56, 44791, Bochum, Germany
29 shared publications- Ralf Gold
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany
16 shared publications Ilya Ayzenberg
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum
7 shared publicationsUlas Ceylan
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany
7 shared publicationsKatharina Klöster
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany
6 shared publicationsKerstin Hellwig
Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum, Germany
6 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1) , 118
Monomethyl Fumarate Modulates Iron Metabolism and Mitochondrial Function in Microglia with Implications for Multiple Sclerosis Progression
Fumaric acid esters have proven to be effective medications in relapsing-remitting multiple sclerosis with neuroprotective effects. In this study, we investigated the impact of fumaric acid esters on primary murine microglia in vitro compared to DMSO vehicle control. Monomethyl fumarate (MMF) increased MTT reduction in a dose-dependent manner, whereas dimethyl fumarate (DMF) exhibited a biphasic response with low concentrations enhancing MTT reduction and higher concentrations inducing toxicity. Notably, complementary analyses of cell number and cell death did not reveal differences between MMF-treated and control conditions, indicating that the increased MTT reduction reflects enhanced cellular metabolic activity rather than increased viability. Consistent with this interpretation, MMF-treated cells exhibited higher basal and maximal oxygen consumption, spare respiratory capacity, and ATP production in the Seahorse XF Cell Mito Stress Test. Proteomic analysis did not indicate an upregulation of mitochondrial respiratory chain proteins, but instead suggested a qualitative shift in mitochondrial homeostasis, including increased expression of mitophagy-associated proteins. MMF-treated Nrf2-deficient microglia showed a blunted increase in MTT reduction, suggesting an involvement of Nrf2 in mediating MMF-induced metabolic effects. Additionally, MMF modulated the microglial iron metabolism and reduced the uptake of non-transferrin-bound iron and altered the gene expression of iron transport proteins, promoting a shift toward the uptake of less toxic, transferrin-bound iron. MMF mitigated iron-induced toxicity and was associated with upregulation of the ferroptosis suppressor protein, indicating a protective response to iron overload. Together, these findings suggest that MMF enhances microglial metabolic activity and mitochondrial function while reducing iron-mediated toxicity, thereby contributing to its neuroprotective effects. Graphical Abstract Summary of the proposed cellular effects of monomethyl fumarate in primary murine microglia. Created in BioRender. Faissner (2026). https://help.biorender.com/hc/en-gb/articles/17605511350685
- 20 July 2026
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 46 (1) , 118
Open AccessMonomethyl Fumarate Modulates Iron Metabolism and Mitochondrial Function in Microglia with Implications for Multiple Sclerosis Progression
Fumaric acid esters have proven to be effective medications in relapsing-remitting multiple sclerosis with neuroprotective effects. In this study, we investigated the impact of fumaric acid esters on primary murine microglia in vitro compared to DMSO vehicle control. Monomethyl fumarate (MMF) increased MTT reduction in a dose-dependent manner, whereas dimethyl fumarate (DMF) exhibited a biphasic response with low concentrations enhancing MTT reduction and higher concentrations inducing toxicity. Notably, complementary analyses of cell number and cell death did not reveal differences between MMF-treated and control conditions, indicating that the increased MTT reduction reflects enhanced cellular metabolic activity rather than increased viability. Consistent with this interpretation, MMF-treated cells exhibited higher basal and maximal oxygen consumption, spare respiratory capacity, and ATP production in the Seahorse XF Cell Mito Stress Test. Proteomic analysis did not indicate an upregulation of mitochondrial respiratory chain proteins, but instead suggested a qualitative shift in mitochondrial homeostasis, including increased expression of mitophagy-associated proteins. MMF-treated Nrf2-deficient microglia showed a blunted increase in MTT reduction, suggesting an involvement of Nrf2 in mediating MMF-induced metabolic effects. Additionally, MMF modulated the microglial iron metabolism and reduced the uptake of non-transferrin-bound iron and altered the gene expression of iron transport proteins, promoting a shift toward the uptake of less toxic, transferrin-bound iron. MMF mitigated iron-induced toxicity and was associated with upregulation of the ferroptosis suppressor protein, indicating a protective response to iron overload. Together, these findings suggest that MMF enhances microglial metabolic activity and mitochondrial function while reducing iron-mediated toxicity, thereby contributing to its neuroprotective effects. Graphical Abstract Summary of the proposed cellular effects of monomethyl fumarate in primary murine microglia. Created in BioRender. Faissner (2026). https://help.biorender.com/hc/en-gb/articles/17605511350685
- RetractionOpen Access
- 13 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Retraction Note: Retinal degeneration driven by brain-derived neurotrophic factor deficiency in microglia and T-lymphocytes
- 13 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
RetractionOpen AccessRetraction Note: Retinal degeneration driven by brain-derived neurotrophic factor deficiency in microglia and T-lymphocytes
- Open Access
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1759831
Severe cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease – case report
Background: Tumor necrosis factor-α (TNF-α) inhibitors such as infliximab are widely used in autoimmune disorders. Paradoxical inflammatory reactions including systemic sarcoidosis and neurosarcoidosis are increasingly recognized but remain rare. Case presentation: We report a 56-year-old male with ulcerative colitis under infliximab therapy presenting with acute dysarthria and gait instability. Neurological examination revealed truncal ataxia. Brain and spinal MRI were normal. Cerebrospinal fluid analysis showed lymphocytic pleocytosis, reduced glucose, increased lactate, and elevated protein with marked blood-brain barrier disruption. Sarcoidosis-associated markers (neopterin, ACE, IL-2 receptor) were elevated. Pulmonary CT and lymph node biopsy confirmed systemic sarcoidosis. Moreover, MOG-antibodies were detected in both serum and CSF. After initial empirical anti-infective therapy, high-dose corticosteroids were initiated, resulting in full recovery. Infliximab therapy was discontinued. Conclusion: This case demonstrates infliximab-associated overlapping autoimmunity with sarcoidosis, probable neurosarcoidosis and MOGAD presenting with acute cerebellitis. Clinicians should consider neurosarcoidosis and MOGAD in patients on TNF-α-inhibitors presenting with neurological deficits, even in the absence of radiological findings. Early discontinuation of the triggering agent and timely corticosteroid therapy are essential for favorable outcomes.
- 1 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1759831
Open AccessSevere cerebellitis as a manifestation of infliximab-associated overlap of neurosarcoidosis and myelin oligodendrocyte glycoprotein antibody-associated disease – case report
Background: Tumor necrosis factor-α (TNF-α) inhibitors such as infliximab are widely used in autoimmune disorders. Paradoxical inflammatory reactions including systemic sarcoidosis and neurosarcoidosis are increasingly recognized but remain rare. Case presentation: We report a 56-year-old male with ulcerative colitis under infliximab therapy presenting with acute dysarthria and gait instability. Neurological examination revealed truncal ataxia. Brain and spinal MRI were normal. Cerebrospinal fluid analysis showed lymphocytic pleocytosis, reduced glucose, increased lactate, and elevated protein with marked blood-brain barrier disruption. Sarcoidosis-associated markers (neopterin, ACE, IL-2 receptor) were elevated. Pulmonary CT and lymph node biopsy confirmed systemic sarcoidosis. Moreover, MOG-antibodies were detected in both serum and CSF. After initial empirical anti-infective therapy, high-dose corticosteroids were initiated, resulting in full recovery. Infliximab therapy was discontinued. Conclusion: This case demonstrates infliximab-associated overlapping autoimmunity with sarcoidosis, probable neurosarcoidosis and MOGAD presenting with acute cerebellitis. Clinicians should consider neurosarcoidosis and MOGAD in patients on TNF-α-inhibitors presenting with neurological deficits, even in the absence of radiological findings. Early discontinuation of the triggering agent and timely corticosteroid therapy are essential for favorable outcomes.
- Open Access
- 11 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (20)
Beyond antibodies in GAD65 autoimmunity: Reframing pathogenesis through intrathecal B–T cell cross-talk
- 11 May 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (20)
Open AccessBeyond antibodies in GAD65 autoimmunity: Reframing pathogenesis through intrathecal B–T cell cross-talk
- Open Access
- 19 March 2026
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 19
Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis
Background: B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or exacerbation of psoriasis under BCDT. Objectives: This article aims to analyze clinical characteristics, treatment courses, and outcomes of MS patients who developed or experienced worsening of psoriasis during BCDT. Design: This retrospective, multicenter analysis included patients from four German university hospitals (Düsseldorf, Hannover, Bochum, Giessen). Methods: We retrospectively screened 3228 MS patients under BCDT between 2020 and 2024 for development of psoriasis or an exacerbation of a known psoriasis. Clinical data, including Expanded Disability Status Scale, Psoriasis Area and Severity Index scores, treatment regimens, and comorbidities, were analyzed. Results: Among 3228 patients treated with BCDT, 7 developed new-onset psoriasis and 10 showed exacerbation of preexisting psoriasis. The median time to psoriasis onset or worsening was 13 months (3–83 months) under continuous treatment with BCDT. Topical therapies were effective in most cases, but a change of MS treatment or initiation of psoriasis-specific immunotherapies, including the interleukin-17A-antibody secukinumab, was required in four patients. Conclusion: Psoriasis onset or worsening during BCDT is rare. While most cases are manageable with standard psoriasis treatments, severe cases may necessitate therapy adjustments. The potential immunological interplay between MS and psoriasis treatment warrants further investigation.
- 19 March 2026
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 19
Open AccessPsoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis
Background: B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or exacerbation of psoriasis under BCDT. Objectives: This article aims to analyze clinical characteristics, treatment courses, and outcomes of MS patients who developed or experienced worsening of psoriasis during BCDT. Design: This retrospective, multicenter analysis included patients from four German university hospitals (Düsseldorf, Hannover, Bochum, Giessen). Methods: We retrospectively screened 3228 MS patients under BCDT between 2020 and 2024 for development of psoriasis or an exacerbation of a known psoriasis. Clinical data, including Expanded Disability Status Scale, Psoriasis Area and Severity Index scores, treatment regimens, and comorbidities, were analyzed. Results: Among 3228 patients treated with BCDT, 7 developed new-onset psoriasis and 10 showed exacerbation of preexisting psoriasis. The median time to psoriasis onset or worsening was 13 months (3–83 months) under continuous treatment with BCDT. Topical therapies were effective in most cases, but a change of MS treatment or initiation of psoriasis-specific immunotherapies, including the interleukin-17A-antibody secukinumab, was required in four patients. Conclusion: Psoriasis onset or worsening during BCDT is rare. While most cases are manageable with standard psoriasis treatments, severe cases may necessitate therapy adjustments. The potential immunological interplay between MS and psoriasis treatment warrants further investigation.
- Open Access
- 15 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1731744
Anti-VGLUT2 autoantibodies associated with post-COVID neurocognitive dysfunction: a case report
Post-COVID-19 syndrome (PCS) is frequently associated with fatigue and cognitive dysfunction, while underlying mechanisms remain unclear. We report a 44-year-old male with persistent symptoms following SARS-CoV-2 infection, including severe cognitive and motor fatigue, word-finding difficulties, and impaired concentration. Neuropsychological testing revealed marked deficits in alertness, attention, fluency, and processing speed. Serum analysis demonstrated anti-VGLUT2 autoantibodies. IVIG therapy yielded subjective but no objective improvement. This appears to be the first PCS case associated with VGLUT2 autoantibodies and raises the hypothesis of a potential pathophysiological link that requires confirmation in larger cohorts.
- 15 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1731744
Open AccessAnti-VGLUT2 autoantibodies associated with post-COVID neurocognitive dysfunction: a case report
Post-COVID-19 syndrome (PCS) is frequently associated with fatigue and cognitive dysfunction, while underlying mechanisms remain unclear. We report a 44-year-old male with persistent symptoms following SARS-CoV-2 infection, including severe cognitive and motor fatigue, word-finding difficulties, and impaired concentration. Neuropsychological testing revealed marked deficits in alertness, attention, fluency, and processing speed. Serum analysis demonstrated anti-VGLUT2 autoantibodies. IVIG therapy yielded subjective but no objective improvement. This appears to be the first PCS case associated with VGLUT2 autoantibodies and raises the hypothesis of a potential pathophysiological link that requires confirmation in larger cohorts.
- Open Access
- 12 January 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (6) , 1222-1235
Effects of Biological Sex and Age on Cerebrospinal Fluid Markers—A Retrospective Observational Study
Objective: Cerebrospinal fluid (CSF) analysis is a key diagnostic tool for neurological diseases. To date, only a few studies have investigated in larger cohorts the effect of age and biological sex on diagnostic markers extracted from CSF. Methods: For this retrospective observational study, 4163 CSF findings (2012–2020) were evaluated. After exclusion of pathogenic CSF findings above or below the locally established reference ranges that are routinely applied in the CSF laboratory for clinical reporting, 1270 findings were included for statistical analysis. Using regression analysis, the relationship between age and CSF markers was illustrated, and regression equations were created. Results: A significant effect of sex was shown for CSF albumin ( p < 0.001; Δ M 29.34), CSF protein ( p < 0.001; Δ M 39.38) and CSF glucose ( p < 0.001; Δ M 3.63) as well as CSF/serum albumin quotient (Q Alb) ( p < 0.001; Δ M 0.57), for Immunoglobulin G in CSF (IgG CSF) ( p < 0.001; Δ M 2.48), CSF/serum IgG quotient (Q IgG) ( p < 0.001; Δ M 0.27), Immunoglobulin A in CSF (IgA CSF) ( p < 0.001; Δ M 0.52), CSF/serum IgA quotient (Q IgA) ( p < 0.001; Δ M 0.15) and CSF/serum IgM quotient (Q IgM) ( p < 0.001; Δ M 0.09). Age showed a significant effect throughout most CSF markers, most strongly for CSF protein ( p < 0.001; η 2 = 0.16) and Q Alb ( p < 0.001; η 2 = 0.23). Both parameters increased significantly with age, leading to higher mean values in older individuals. Interpretation: For almost all markers in CSF, a significant effect of age alone on the markers or a significant effect of sex and age on the markers could be detected. Our study underscores the importance of age‐ and sex‐adjusted reference values for the interpretation of CSF markers in clinical practice.
- 12 January 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 13 (6) , 1222-1235
Open AccessEffects of Biological Sex and Age on Cerebrospinal Fluid Markers—A Retrospective Observational Study
Objective: Cerebrospinal fluid (CSF) analysis is a key diagnostic tool for neurological diseases. To date, only a few studies have investigated in larger cohorts the effect of age and biological sex on diagnostic markers extracted from CSF. Methods: For this retrospective observational study, 4163 CSF findings (2012–2020) were evaluated. After exclusion of pathogenic CSF findings above or below the locally established reference ranges that are routinely applied in the CSF laboratory for clinical reporting, 1270 findings were included for statistical analysis. Using regression analysis, the relationship between age and CSF markers was illustrated, and regression equations were created. Results: A significant effect of sex was shown for CSF albumin ( p < 0.001; Δ M 29.34), CSF protein ( p < 0.001; Δ M 39.38) and CSF glucose ( p < 0.001; Δ M 3.63) as well as CSF/serum albumin quotient (Q Alb) ( p < 0.001; Δ M 0.57), for Immunoglobulin G in CSF (IgG CSF) ( p < 0.001; Δ M 2.48), CSF/serum IgG quotient (Q IgG) ( p < 0.001; Δ M 0.27), Immunoglobulin A in CSF (IgA CSF) ( p < 0.001; Δ M 0.52), CSF/serum IgA quotient (Q IgA) ( p < 0.001; Δ M 0.15) and CSF/serum IgM quotient (Q IgM) ( p < 0.001; Δ M 0.09). Age showed a significant effect throughout most CSF markers, most strongly for CSF protein ( p < 0.001; η 2 = 0.16) and Q Alb ( p < 0.001; η 2 = 0.23). Both parameters increased significantly with age, leading to higher mean values in older individuals. Interpretation: For almost all markers in CSF, a significant effect of age alone on the markers or a significant effect of sex and age on the markers could be detected. Our study underscores the importance of age‐ and sex‐adjusted reference values for the interpretation of CSF markers in clinical practice.
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200479
Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis
Autologous chimeric antigen receptor (CAR) T-cell therapy has recently gained interest in the treatment of rheumatic and neuroimmunologic diseases. We report a 62-year-old female patient with a 14-year history of treatment-refractory anti-GAD-positive stiff-person syndrome (SPS) and concomitant anti-AChR-positive myasthenia gravis. Despite a relatively stable disease course in the first 8 years, SPS dramatically progressed afterward. In 2023, she was able to walk less than 10-15 m and suffered from severe persistent stiffness in the left arm superimposed with painful muscle spasm attacks (MSAs). Numerous immunotherapies, including intravenous immunoglobulins, plasma exchange, steroids, azathioprine, and rituximab, were ineffective. Consequently, she was escalated to compassionate use of autologous anti-CD19 CAR T-cell therapy (KYV-101). From the third month post-CAR-T, we observed a substantial improvement in walking distance, pain, anxiety, and MSAs in the arm. By the sixth month, she was able to walk 500 m. The anti-GAD titers declined from 1:320 to 1:32. Side effects included grade 2 cytokine release syndrome and moderate leukopenia, without serious infections. CAR T-cell therapy was effective at mitigating SPS symptoms, despite the long history and severe refractory disease course in our patient. Controlled trials are needed to evaluate its potential in SPS.
- 1 November 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (6) , e200479
Open AccessAnti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis
Autologous chimeric antigen receptor (CAR) T-cell therapy has recently gained interest in the treatment of rheumatic and neuroimmunologic diseases. We report a 62-year-old female patient with a 14-year history of treatment-refractory anti-GAD-positive stiff-person syndrome (SPS) and concomitant anti-AChR-positive myasthenia gravis. Despite a relatively stable disease course in the first 8 years, SPS dramatically progressed afterward. In 2023, she was able to walk less than 10-15 m and suffered from severe persistent stiffness in the left arm superimposed with painful muscle spasm attacks (MSAs). Numerous immunotherapies, including intravenous immunoglobulins, plasma exchange, steroids, azathioprine, and rituximab, were ineffective. Consequently, she was escalated to compassionate use of autologous anti-CD19 CAR T-cell therapy (KYV-101). From the third month post-CAR-T, we observed a substantial improvement in walking distance, pain, anxiety, and MSAs in the arm. By the sixth month, she was able to walk 500 m. The anti-GAD titers declined from 1:320 to 1:32. Side effects included grade 2 cytokine release syndrome and moderate leukopenia, without serious infections. CAR T-cell therapy was effective at mitigating SPS symptoms, despite the long history and severe refractory disease course in our patient. Controlled trials are needed to evaluate its potential in SPS.
- Open Access
- 27 October 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (6)
Eomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy
Multiple sclerosis is a chronic inflammatory disease affecting the central nervous system. While treatment made huge advances, progression remains a challenge. Eomesodermin+ Th cells are associated with cytotoxicity, neuroinflammation and disease progression in secondary progressive multiple sclerosis. We performed a prospective longitudinal study over one year to investigate the role of Eomesodermin+ T cells in multiple sclerosis progression and neurodegeneration. Patients underwent detailed clinical assessment and immunophenotyping. In a subcohort of patients, cross-sectional magnetic resonance imaging using voxel-based morphometry was performed. Frequencies of Eomesodermin+ Th cells could differentiate between patients with secondary and primary progressive multiple sclerosis and correlated with B-cells in secondary progressive multiple sclerosis. Secondary progressive patients experiencing a subjective worsening of disease activity showed higher baseline frequencies of Eomesodermin+ Th cells. Higher baseline frequencies of Eomesodermin+ Th cells predicted prospective one-year disability progression in a small group of secondary progressive patients. Conclusively, voxel-based morphometry analysis revealed pronounced infratentorial brain atrophy in a sub-cohort of patients with higher Eomesodermin+ Th frequencies. In summary, Eomesodermin+ Th cells may shape a dysregulated and proinflammatory immune milieu, driving disease progression and neurodegeneration in secondary progressive multiple sclerosis with potential as both biomarker and therapeutic target.
- 27 October 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 7 (6)
Open AccessEomesodermin-expressing CD4 Th cells and association with multiple sclerosis progression and brain atrophy
Multiple sclerosis is a chronic inflammatory disease affecting the central nervous system. While treatment made huge advances, progression remains a challenge. Eomesodermin+ Th cells are associated with cytotoxicity, neuroinflammation and disease progression in secondary progressive multiple sclerosis. We performed a prospective longitudinal study over one year to investigate the role of Eomesodermin+ T cells in multiple sclerosis progression and neurodegeneration. Patients underwent detailed clinical assessment and immunophenotyping. In a subcohort of patients, cross-sectional magnetic resonance imaging using voxel-based morphometry was performed. Frequencies of Eomesodermin+ Th cells could differentiate between patients with secondary and primary progressive multiple sclerosis and correlated with B-cells in secondary progressive multiple sclerosis. Secondary progressive patients experiencing a subjective worsening of disease activity showed higher baseline frequencies of Eomesodermin+ Th cells. Higher baseline frequencies of Eomesodermin+ Th cells predicted prospective one-year disability progression in a small group of secondary progressive patients. Conclusively, voxel-based morphometry analysis revealed pronounced infratentorial brain atrophy in a sub-cohort of patients with higher Eomesodermin+ Th frequencies. In summary, Eomesodermin+ Th cells may shape a dysregulated and proinflammatory immune milieu, driving disease progression and neurodegeneration in secondary progressive multiple sclerosis with potential as both biomarker and therapeutic target.
- Open Access
- 14 October 2025
- Published by Wiley in Developmental Neurobiology
- Vol. 85 (4) , e23003
Neurodevelopmental Impact of Prenatal Stress: A Proteomic Analysis of Myelination Disruptions in the Avian Embryo
Prenatal stress, mediated by elevated glucocorticoid (GC) levels, is a relevant modulator of fetal brain development and a known risk factor for neurodevelopmental disorders. Using the avian embryo as a vertebrate model, we injected corticosterone into the yolk on embryonic day 6 (E6) and assessed neurodevelopmental outcomes at day 14 (E14). Through deep proteomic profiling — quantifying over 6500 proteins — we uncovered a robust molecular signature of stress‐induced disruption. Key myelin‐associated proteins (myelin basic protein [MBP], PLP1, 2′,3′‐cyclic‐nucleotide 3′‐phosphodiesterase [CNP]) were markedly downregulated, indicating impaired oligodendrocyte maturation. These proteomic shifts were corroborated by immunohistochemistry and qPCR. Pathway‐level analysis pointed to altered MAPK and AKT signaling as putative mediators of the observed phenotype. Our findings mirror previous mammalian data while highlighting the avian model's unique suitability for mechanistic dissection of prenatal stress effects. This study offers new insight into how early GC exposure impairs glial development, with broader implications for understanding the molecular origins of stress‐linked brain vulnerability.
- 14 October 2025
- Published by Wiley in Developmental Neurobiology
- Vol. 85 (4) , e23003
Open AccessNeurodevelopmental Impact of Prenatal Stress: A Proteomic Analysis of Myelination Disruptions in the Avian Embryo
Prenatal stress, mediated by elevated glucocorticoid (GC) levels, is a relevant modulator of fetal brain development and a known risk factor for neurodevelopmental disorders. Using the avian embryo as a vertebrate model, we injected corticosterone into the yolk on embryonic day 6 (E6) and assessed neurodevelopmental outcomes at day 14 (E14). Through deep proteomic profiling — quantifying over 6500 proteins — we uncovered a robust molecular signature of stress‐induced disruption. Key myelin‐associated proteins (myelin basic protein [MBP], PLP1, 2′,3′‐cyclic‐nucleotide 3′‐phosphodiesterase [CNP]) were markedly downregulated, indicating impaired oligodendrocyte maturation. These proteomic shifts were corroborated by immunohistochemistry and qPCR. Pathway‐level analysis pointed to altered MAPK and AKT signaling as putative mediators of the observed phenotype. Our findings mirror previous mammalian data while highlighting the avian model's unique suitability for mechanistic dissection of prenatal stress effects. This study offers new insight into how early GC exposure impairs glial development, with broader implications for understanding the molecular origins of stress‐linked brain vulnerability.